» Articles » PMID: 9202712

Versatile Vectors for Transient and Stable Expression of Recombinant Antibody Molecules in Mammalian Cells

Overview
Publisher Elsevier
Date 1997 May 12
PMID 9202712
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

We have developed new cassette expression vectors for the cloning of any intact V-region gene followed by any C-region gene. Both the heavy-and light chain vectors harbor a strong hCMV promoter, restriction site cassettes for cloning of both V- and C-region genes, transcription termination signals, fl-ori for single stranded DNA (ssDNA) synthesis, selection marker for Neomycin and SV40 ori for transient expression. The vectors accept VH and VL chain genes obtained by RT-PCR. Reamplification of the V genes is then performed with a new set of primers which are designed specifically for each individual V gene. Cloning into the vectors is aided by restriction sites located just outside the V-gene coding region, thus keeping the V-genes intact. The vectors also contain cloning sites for the exchange of genomic C-genes so that the resulting Ig genes may code for complete antibodies, antibody fragments or fusion proteins. A simple subcloning step permits the expression of both heavy and light chain genes from one single vector, thus avoiding co-transfection of the two vectors. The usefulness of the vectors was confirmed by construction of mouse-human chimeric antibodies. The V-genes were derived from a hybridoma cell line, TP-3, and was combined with human C kappa, C gamma 3 and C gamma 1 genes as well as with CH1 gamma 3. High yields of recombinant antibody products in NSO cells were obtained. Transient expression was also demonstrated.

Citing Articles

Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria.

Foss S, Sakya S, Aguinagalde L, Lustig M, Shaughnessy J, Cruz A Nat Commun. 2024; 15(1):2007.

PMID: 38453922 PMC: 10920689. DOI: 10.1038/s41467-024-46321-9.


Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins.

Hinke D, Anderson A, Katta K, Laursen M, Tesfaye D, Werninghaus I Nat Commun. 2024; 15(1):850.

PMID: 38346952 PMC: 10861589. DOI: 10.1038/s41467-024-44889-w.


Id-neoantigen vaccine induces therapeutic CD8 T cells against multiple myeloma: H chain-loss escapees cause FLC MM.

Westhrin M, Blazevski J, Textor A, Abdollahi P, Gopalakrishnan R, Ngo L J Immunother Cancer. 2023; 11(8).

PMID: 37607769 PMC: 10445383. DOI: 10.1136/jitc-2023-006944.


Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models.

Mukadam A, Miller L, Smith A, Vaysburd M, Sakya S, Sanford S Science. 2023; 379(6639):1336-1341.

PMID: 36996217 PMC: 7614512. DOI: 10.1126/science.abn1366.


Neuraminidase delivered as an APC-targeted DNA vaccine induces protective antibodies against influenza.

Werninghaus I, Hinke D, Fossum E, Bogen B, Braathen R Mol Ther. 2023; 31(7):2188-2205.

PMID: 36926694 PMC: 10362400. DOI: 10.1016/j.ymthe.2023.03.012.